Skip to main content
PMC home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 2003 Aug;79(4):270–275. doi: 10.1136/sti.79.4.270

Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts

C Lacey 1, R Goodall 1, T Ragnarson 1, R Maw 1, G Kinghorn 1, P Fisk 1, S Barton 1, I Byren 1
PMCID: PMC1744726  PMID: 12902571

Abstract

Objectives: To evaluate the efficacy and cost effectiveness of self applied podophyllotoxin 0.5% solution and podophyllotoxin 0.15% cream, compared to clinic applied 25% podophyllin in the treatment of genital warts over 4 weeks.

Methods: We conducted a randomised controlled trial in 358 immunocompetent men and women with genital warts of 3 months' duration or less.

Results: In the principal analysis both podophyllotoxin solution (OR 2.93, 95% CI 1.56 to 5.50) and podophyllotoxin cream (OR 1.97, 95% CI 1.04 to 3.70) were associated with significantly increased odds of remission of all warts compared to podophyllin. We performed two further analyses. When subjects defaulting from follow up were assumed to have been cured odds of remission of all warts were also significantly increased both for podophyllotoxin solution (OR 3.04, 95% CI 1.68 to 5.49) and for podophyllotoxin cream (OR 2.46, 95% CI 1.38 to 4.40). When subjects defaulting from follow up were assumed not to have been cured odds of remission of all warts were significantly increased for podophyllotoxin solution (OR 1.92, 95% CI 1.13 to 3.27), but not for podophyllotoxin cream (OR 1.17, 95% CI 0.69 to 2.00). Local side effects were seen in 24% of subjects, and recurrence of warts within 12 weeks of study entry in 43% of all initially cleared subjects, without statistically significant differences between the treatment groups. Direct, indirect, and total costs were similar across the three treatment groups. Podophyllotoxin solution was the most cost effective treatment, followed by podophyllotoxin cream, with podophyllin treatment being the least cost effective.

Conclusions: Self treatment of anogenital warts with podophyllotoxin showed greater efficacy and cost effectiveness than clinic based treatment with podophyllin.

Full Text

The Full Text of this article is available as a PDF (151.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alam M., Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol. 2001 Mar;137(3):337–341. [PubMed] [Google Scholar]
  2. Beutner K. R., Ferenczy A. Therapeutic approaches to genital warts. Am J Med. 1997 May 5;102(5A):28–37. doi: 10.1016/s0002-9343(97)00181-2. [DOI] [PubMed] [Google Scholar]
  3. Claesson U., Lassus A., Happonen H., Hogström L., Siboulet A. Topical treatment of venereal warts: a comparative open study of podophyllotoxin cream versus solution. Int J STD AIDS. 1996 Oct;7(6):429–434. doi: 10.1258/0956462961918400. [DOI] [PubMed] [Google Scholar]
  4. Coleman N., Birley H. D., Renton A. M., Hanna N. F., Ryait B. K., Byrne M., Taylor-Robinson D., Stanley M. A. Immunological events in regressing genital warts. Am J Clin Pathol. 1994 Dec;102(6):768–774. doi: 10.1093/ajcp/102.6.768. [DOI] [PubMed] [Google Scholar]
  5. Drummond M. F., Davies L. Economic analysis alongside clinical trials. Revisiting the methodological issues. Int J Technol Assess Health Care. 1991;7(4):561–573. doi: 10.1017/s0266462300007121. [DOI] [PubMed] [Google Scholar]
  6. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics. 1992 Jul;2(1):1–4. doi: 10.2165/00019053-199202010-00001. [DOI] [PubMed] [Google Scholar]
  7. Gross G., Ikenberg H., Gissmann L., Hagedorn M. Papillomavirus infection of the anogenital region: correlation between histology, clinical picture, and virus type. Proposal of a new nomenclature. J Invest Dermatol. 1985 Aug;85(2):147–152. doi: 10.1111/1523-1747.ep12276576. [DOI] [PubMed] [Google Scholar]
  8. Hellberg D., Svarrer T., Nilsson S., Valentin J. Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. Int J STD AIDS. 1995 Jul-Aug;6(4):257–261. doi: 10.1177/095646249500600407. [DOI] [PubMed] [Google Scholar]
  9. Kinghorn G. R., McMillan A., Mulcahy F., Drake S., Lacey C., Bingham J. S. An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS. 1993 Jul-Aug;4(4):194–199. doi: 10.1177/095646249300400403. [DOI] [PubMed] [Google Scholar]
  10. Koopmanschap M. A., Rutten F. F. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics. 1993 Dec;4(6):446–454. doi: 10.2165/00019053-199304060-00006. [DOI] [PubMed] [Google Scholar]
  11. Lassus A. Comparison of podophyllotoxin and podophyllin in treatment of genital warts. Lancet. 1987 Aug 29;2(8557):512–513. doi: 10.1016/s0140-6736(87)91823-x. [DOI] [PubMed] [Google Scholar]
  12. Maw R. D., Reitano M., Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS. 1998 Oct;9(10):571–578. doi: 10.1258/0956462981921143. [DOI] [PubMed] [Google Scholar]
  13. Mohanty K. C. The cost effectiveness of treatment of genital warts with podophyllotoxin. Int J STD AIDS. 1994 Jul-Aug;5(4):253–256. doi: 10.1177/095646249400500405. [DOI] [PubMed] [Google Scholar]
  14. Persson G., Andersson K., Krantz I. Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture. Acta Obstet Gynecol Scand. 1996 Mar;75(3):287–290. doi: 10.3109/00016349609047103. [DOI] [PubMed] [Google Scholar]
  15. Strand A., Brinkeborn R. M., Siboulet A. Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution. Genitourin Med. 1995 Dec;71(6):387–390. doi: 10.1136/sti.71.6.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Strauss M. J., Khanna V., Koenig J. D., Downs S. M., Goldberg S. H., Manyak M. J., Patsner B. The cost of treating genital warts. Int J Dermatol. 1996 May;35(5):340–348. doi: 10.1111/j.1365-4362.1996.tb03635.x. [DOI] [PubMed] [Google Scholar]
  17. Tyring S., Edwards L., Cherry L. K., Ramsdell W. M., Kotner S., Greenberg M. D., Vance J. C., Barnum G., Dromgoole S. H., Killey F. P. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol. 1998 Jan;134(1):33–38. doi: 10.1001/archderm.134.1.33. [DOI] [PubMed] [Google Scholar]
  18. von Krogh G., Maibach H. I. Cutaneous cytodestructive potency of lignans. I. A comparative evaluation of influence on epidermal and dermal DNA synthesis and on dermal microcirculation in the hairless mouse. Arch Dermatol Res. 1982;274(1-2):9–20. doi: 10.1007/BF00510353. [DOI] [PubMed] [Google Scholar]
  19. von Krogh G. Penile condylomata acuminata: an experimental model for evaluation of topical self-treatment with 0.5--1.0% ethanolic preparations of podophyllotoxin for three days. Sex Transm Dis. 1981 Jul-Sep;8(3):179–186. [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES